Jonas Odgaard Petersen

Co-founder of Ousia Pharma. Postdoctoral fellow working on development of novel anti-obesity medicines. Chemistry.

[Jonas Odgaard Petersen @OdgaardJonas]

Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!

https://t.co/LLDn8oVbph

1/7 🧵

[Jonas Odgaard Petersen @OdgaardJonas]

📚In our Review, we synthesize the rapidly expanding knowledge across the field from the clinical breakthroughs that have reshaped obesity treatment, to the molecular mechanisms behind the next generation of obesity therapies now moving through the pipeline.

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2

This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2

This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

[Christoffer Clemmensen @ClemmensenC]

1/8
🧠 New review from the lab in @CellCellPress: Brain Control of Energy Homeostasis

We explore how central nervous system circuits regulate energy balance, and how this informs the development of next-generation obesity pharmacotherapies.
🔗 https://t.co/9OaWTO2cKy

[Jonas Odgaard Petersen @OdgaardJonas]

Thrilled to have contributed to this snapshot article on "Brain-Targeting Anti-Obesity Medications" appearing today in @Cell_Metabolism on #WorldObesityDay.

[Christoffer Clemmensen @ClemmensenC]

On #WorldObesityDay, we have contributed a SnapShot to a special Issue on Obesity in @Cell_Metabolism covering brain actions of the current and emerging weight loss drugs. @OdgaardJonas @JohansenVBI
@UCPH_health

Free access link: https://t.co/87NUv3EfPg

[Christoffer Clemmensen @ClemmensenC]

1/4 New paper out in @MolMetab in which we show that calorie restriction before starting treatment with semaglutide or tirzepatide pushes maximum achievable weight loss by ~8% https://t.co/sVjfY5jdnD

[Christoffer Clemmensen @ClemmensenC]

A few months back, we published a study in @ScienceAdvances demonstrating the potential of targeting postsynaptic glutamate receptor scaffolding proteins, such as PSD-95, for sustained weight loss. Headed by @nicolefadahunsi, @OdgaardJonas and @Met_Sop https://t.co/lJtsrirdTP

[Luca Laraia @laraialab]

Big day for the lab as our latest paper is out in Nature Chemical Biology @nchembio on identifying the oxybipins as new OSBP inhibitors, as well as their mechanism of action and therapeutic applications! https://t.co/oP2HIcDiUT 1/n

[Jonas Odgaard Petersen @OdgaardJonas]

@alexshauser @NatMetabolism Congratulations on publishing this amazing piece of work! 🥳Very important for understanding the complexities of GIP-based anti-obesity medicines.

[Christoffer Clemmensen @ClemmensenC]

Research Highlight in @NatRevDrugDisc covering our recent paper on targeted NMDA receptor antagonism for obesity treatment https://t.co/NI1i5dAwmo

[Jonas Odgaard Petersen @OdgaardJonas]

@WFelixZhu @Nature Thank you!

[Jonas Odgaard Petersen @OdgaardJonas]

Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!

https://t.co/LLDn8oVbph

1/7 🧵

[Jonas Odgaard Petersen @OdgaardJonas]

@FenselauHenning @Nature Thank you very much! 🙌🏼

[Jonas Odgaard Petersen @OdgaardJonas]

@itsmedipsikha @Nature Thank you! ☺️

[Jonas Odgaard Petersen @OdgaardJonas]

@alexshauser @Nature Thank you, Alex! 🙏🏼

[Jonas Odgaard Petersen @OdgaardJonas]

@yuexu4real @Nature Thank you!

[Christoffer Clemmensen @ClemmensenC]

Insightful News and Views´ from @Tcook30 and @DarleenSandoval on our recent paper.

[Jonas Odgaard Petersen @OdgaardJonas]

@alexanderln91 @Nature Thank you! 😄

[Jonas Odgaard Petersen @OdgaardJonas]

@JosephRogers100 😂😂

[Jonas Odgaard Petersen @OdgaardJonas]

@thewilliamslab Thank you! It has been amazing working together with you and your lab!

[Jonas Odgaard Petersen @OdgaardJonas]

7/7 Kudos to all the people involved in this massive collaborative effort from the labs of @ClemmensenC @stromgaardlab @Froelund_lab @tunepers @thewilliamslab @KAKohlmier @atul_deshmukh1 @Thue_Schwartz and @MortenBThomsen from @Metabolcenter at @koebenhavns_uni @UCPH_health

[Jonas Odgaard Petersen @OdgaardJonas]

4/7 To safely harvest the appetite-modulating effects of NMDAR antagonism, we engineered a first-in-class dual-acting compound that chemically combines GLP-1R agonism and NMDAR antagonism in a single Trojan horse like molecule.

[Jonas Odgaard Petersen @OdgaardJonas]

6/7 Check out the informative thread by @ClemmensenC. It has been absolutely amazing working on this piece together, and I am excited to continue working on the next-generation of compounds in @OusiaPharma together with @BueKlein with support from @BioCPH and @Innofond .